Eylea (aflibercept) is a biologic drug prescribed to help prevent vision loss in certain situations. It’s a liquid solution given by healthcare professionals as an injection into the eye.

TARRYTOWN, N.Y., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new analyses of EYLEA HD® (aflibercept) Injection 8 mg and EYLEA® (aflibercept ...

Everyone received a shot once every month when the studies started, but then the injection schedule changed. After the first 3 months, the people who used Eylea received an injection either every ...

Globally, RVO affects over 28 million people. EYLEA HD® (aflibercept) Injection 8 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are ...

EYLEA HD was developed to achieve comparable efficacy and safety to EYLEA, but with fewer injections. EYLEA HD is supported by a robust body of research and is currently approved in the U.S. to ...

Digital access Digital + home delivery TSX-0.04 % ...